<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-044766</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases</dc:title>
<dc:description xml:lang="en">Pharmacological intervention on the immune system to achieve more intense lymphocyte responses has potential application in tumour immunology and in the treatment of chronic viral diseases. Immunostimulating monoclonal antibodies are defined as a new family of drugs that augment cellular immune responses. They interact as artificial ligands with functional proteins of the immune system, either activating or inhibiting their functions. There are humanized monoclonal antibodies directed to the inhibitory receptor CD152 (CTLA-4) that are being tested in clinical trials with evidence of antitumoural activity. As a drawback, anti-CTLA-4 monoclonal antibodies induce severe autoimmunity reactions in a fraction of the patients. Anti-CD137 monoclonal antibodies have the ability to induce potent immune responses mainly mediated by cytotoxic lymphocytes with the result of frequent complete tumour eradications in mice. Comparative studies in experimental models indicate that the antitumour activity of anti-CD137 monoclonal antibodies is superior to that of anti-CD152. CD137 (4-1BB) is a leukocyte differentiation antigen selectively expressed on the surface of activated T and NK lymphocytes, as well as on dendritic cells. Monoclonal antibodies acting as artificial stimulatory ligands of this receptor (anti-CD137 agonist antibodies) enhance cellular antitumoural and antiviral immunity in a variety of mouse models. Paradoxically, anti-CD137 monoclonal antibodies are therapeutic or preventive in the course of model autoimmune diseases in mice. In light of these experimental results, a number of research groups have humanized antibodies against human CD137 and early clinical trials are about to start</dc:description>
<dc:creator>Tirapu, I</dc:creator>
<dc:creator>Arribillaga, L</dc:creator>
<dc:creator>Pérez-Gracia, J. L</dc:creator>
<dc:creator>Lasarte, J. J</dc:creator>
<dc:creator>Alfaro, C</dc:creator>
<dc:creator>Azpilicueta, A</dc:creator>
<dc:creator>Melero, I</dc:creator>
<dc:creator>Arina, A</dc:creator>
<dc:creator>Murillo, O</dc:creator>
<dc:creator>Prieto, J</dc:creator>
<dc:creator>Huarte, E</dc:creator>
<dc:creator>Bendandi, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La manipulación farmacológica del sistema inmunitario para conseguir respuestas linfocitarias de mayor intensidad tiene aplicación potencial en inmunoterapia tumoral y en el tratamiento de enfermedades virales crónicas. Los anticuerpos monoclonales inmunoestimuladores se definen como una familia de fármacos que aumentan la respuesta inmunitaria al interaccionar como ligandos artificiales con proteínas funcionales del sistema inmunitario, activando o inhibiendo su función. Hay anticuerpos monoclonales humanizados dirigidos frente al receptor inhibidor linfocitario CD152 (CTLA-4) que se están probando en ensayos clínicos con evidencia de actividad antitumoral, aunque con la contrapartida de producir reacciones autoinmunitarias severas. Los anticuerpos anti-CD137 tienen la capacidad de inducir potentes respuestas inmunitarias, mediadas principalmente por linfocitos T citotóxicos, con el resultado de erradicar tumores transplantables de ratón de forma comparativamente superior a los anticuerpos frente a CD152. CD137 (4-1BB) es un antígeno de diferenciación expresado selectivamente en la superficie de linfocitos T y NK activados y sobre células dendríticas. Los anticuerpos monoclonales que actúan como ligandos artificiales estimuladores de este receptor (anticuerpos monoclonales agonistas anti-CD137) potencian la inmunidad celular antitumoral y antiviral en modelos experimentales murinos. Paradójicamente, estos mismos anticuerpos previenen o mejoran el curso de enfermedades autoinmunitarias establecidas en ratones como modelo. A la luz de estos datos experimentales, varios grupos de investigación han procedido a la humanización de anticuerpos dirigidos frente a CD137 humano y se plantea la inminente realización de los primeros ensayos clínicos</dc:description>
<dc:source>An Sist Sanit Navar;29(1): 77-96, ene.-abr. 2006. ilus</dc:source>
<dc:identifier>ibc-044766</dc:identifier>
<dc:title xml:lang="es">El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones virales crónicas</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d8994</dc:subject>
<dc:subject>^d7345</dc:subject>
<dc:subject>^d24524^s22038</dc:subject>
<dc:subject>^d23126^s22073</dc:subject>
<dc:subject>^d28622</dc:subject>
<dc:subject>^d9562^s22038</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23045</dc:subject>
<dc:subject>^d9567^s22038</dc:subject>
<dc:subject>^d30551^s22038</dc:subject>
<dc:subject>^d28563</dc:subject>
<dc:subject>^d24016^s22038</dc:subject>
<dc:subject>^d33062^s22073</dc:subject>
<dc:subject>^d28903^s22038</dc:subject>
<dc:subject>^d24529</dc:subject>
<dc:subject>^d14575</dc:subject>
<dc:subject>^d841</dc:subject>
<dc:subject>^d22944</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d974^s22073</dc:subject>
<dc:subject>^d21079^s22067</dc:subject>
<dc:subject>^d29359^s22038</dc:subject>
<dc:subject>^d31092^s22038</dc:subject>
<dc:type>article</dc:type>
<dc:date>200604</dc:date>
</metadata>
</record>
</ibecs-document>
